TY - JOUR
T1 - One-year results of a factorial randomized trial of Aspirin versus placebo and clonidine versus placebo in patients having noncardiac surgery
AU - Sessler, Daniel I.
AU - Conen, David
AU - Leslie, Kate
AU - Yusuf, Salim
AU - Popova, Ekaterina
AU - Graham, Michelle
AU - Kurz, Andrea
AU - Villar, Juan Carlos
AU - Mrkobrada, Marko
AU - Sigamani, Alben
AU - Biccard, Bruce M.
AU - Meyhoff, Christian S.
AU - Parlow, Joel L.
AU - Guyatt, Gordon
AU - Xavier, Denis
AU - Chan, Matthew T.V.
AU - Kumar, Priya A.
AU - Forget, Patrice
AU - Malaga, German
AU - Fleischmann, Edith
AU - Amir, Mohammed
AU - Torres, David
AU - Wang, C. Y.
AU - Paniagua, Pilar
AU - Berwanger, Otavio
AU - Srinathan, Sadeesh
AU - Landoni, Giovanni
AU - Le Manach, Yannick
AU - Whitlock, Richard
AU - Lamy, André
AU - Balasubramanian, Kumar
AU - Gilron, Ian
AU - Turan, Alparslan
AU - Pettit, Shirley
AU - Devereaux, P. J.
N1 - Publisher Copyright:
Copyright © 2020, the American Society of Anesthesiologists, Inc. All Rights Reserved.
PY - 2020
Y1 - 2020
N2 - Background: The authors previously reported that perioperative aspirin and/or clonidine does not prevent a composite of death or myocardial infarction 30 days after noncardiac surgery. Moreover, aspirin increased the risk of major bleeding and clonidine caused hypotension and bradycardia. Whether these complications produce harm at 1 yr remains unknown. Methods: The authors randomized 10,010 patients with or at risk of atherosclerosis and scheduled for noncardiac surgery in a 1:1:1:1 ratio to clonidine/aspirin, clonidine/aspirin placebo, clonidine placebo/aspirin, or clonidine placebo/aspirin placebo. Patients started taking aspirin or placebo just before surgery; those not previously taking aspirin continued daily for 30 days, and those taking aspirin previously continued for 7 days. Patients were also randomly assigned to receive clonidine or placebo just before surgery, with the study drug continued for 72 h. results: Neither aspirin nor clonidine had a significant effect on the primary 1-yr outcome, a composite of death or nonfatal myocardial infarction, with a 1-yr hazard ratio for aspirin of 1.00 (95% CI, 0.89 to 1.12; P = 0.948; 586 patients [11.8%] vs. 589 patients [11.8%]) and a hazard ratio for clonidine of 1.07 (95% CI, 0.96 to 1.20; P = 0.218; 608 patients [12.1%] vs. 567 patients [11.3%]), with effect on death or nonfatal infarction. Reduction in death and nonfatal myocardial infarction from aspirin in patients who previously had percutaneous coronary intervention at 30 days persisted at 1 yr. Specifically, the hazard ratio was 0.58 (95% CI, 0.35 to 0.95) in those with previous percutaneous coronary intervention and 1.03 (95% CI, 0.91to 1.16) in those without (interaction P = 0.033). There was no significant effect of either drug on death, cardiovascular complications, cancer, or chronic incisional pain at 1 yr (all P > 0.1). conclusions: Neither perioperative aspirin nor clonidine have significant long-term effects after noncardiac surgery. Perioperative aspirin in patients with previous percutaneous coronary intervention showed persistent benefit at 1 yr, a plausible sub-group effect.
AB - Background: The authors previously reported that perioperative aspirin and/or clonidine does not prevent a composite of death or myocardial infarction 30 days after noncardiac surgery. Moreover, aspirin increased the risk of major bleeding and clonidine caused hypotension and bradycardia. Whether these complications produce harm at 1 yr remains unknown. Methods: The authors randomized 10,010 patients with or at risk of atherosclerosis and scheduled for noncardiac surgery in a 1:1:1:1 ratio to clonidine/aspirin, clonidine/aspirin placebo, clonidine placebo/aspirin, or clonidine placebo/aspirin placebo. Patients started taking aspirin or placebo just before surgery; those not previously taking aspirin continued daily for 30 days, and those taking aspirin previously continued for 7 days. Patients were also randomly assigned to receive clonidine or placebo just before surgery, with the study drug continued for 72 h. results: Neither aspirin nor clonidine had a significant effect on the primary 1-yr outcome, a composite of death or nonfatal myocardial infarction, with a 1-yr hazard ratio for aspirin of 1.00 (95% CI, 0.89 to 1.12; P = 0.948; 586 patients [11.8%] vs. 589 patients [11.8%]) and a hazard ratio for clonidine of 1.07 (95% CI, 0.96 to 1.20; P = 0.218; 608 patients [12.1%] vs. 567 patients [11.3%]), with effect on death or nonfatal infarction. Reduction in death and nonfatal myocardial infarction from aspirin in patients who previously had percutaneous coronary intervention at 30 days persisted at 1 yr. Specifically, the hazard ratio was 0.58 (95% CI, 0.35 to 0.95) in those with previous percutaneous coronary intervention and 1.03 (95% CI, 0.91to 1.16) in those without (interaction P = 0.033). There was no significant effect of either drug on death, cardiovascular complications, cancer, or chronic incisional pain at 1 yr (all P > 0.1). conclusions: Neither perioperative aspirin nor clonidine have significant long-term effects after noncardiac surgery. Perioperative aspirin in patients with previous percutaneous coronary intervention showed persistent benefit at 1 yr, a plausible sub-group effect.
U2 - 10.1097/ALN.0000000000003158
DO - 10.1097/ALN.0000000000003158
M3 - Journal article
C2 - 32022771
AN - SCOPUS:85082147114
SP - 692
EP - 701
JO - Anesthesiology
JF - Anesthesiology
SN - 0003-3022
ER -